Bone-loss-related diseases, such as periodontitis, are characterized by an imbalance between the formation and activity of osteoblasts and osteoclasts, leading to bone loss. There are several signaling pathways that participate in the osteoclastogenesis process. Finding inhibitors of these pathways and other osteoclastogenesis-related pathways may have an effect on bone-loss diseases.
Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of Campinas, Brazil, have identified cinnamolyoxy-mammeisin (CNM), a 4-phenylcoumarin, which can be isolated from Brazilian geopropolis, as active against osteoclastogeneis pathways. CNM demonstrates anti-inflammatory activity and inhibition of oral bone loss in a mouse model of periodontitis.
- Alternative to commercial antiresorptive agents
- Lack of cytotoxicity
John Beutler (NCI), Marco da Cunha, Pedro Rosalen, Marcelo Franchin
Da Cunha M, et al. Effects of Cinnamoyloxy-mammeisin from Geopropolis on Osteoclast Differentiation and Porphyromonas gingivalis-Induced Periodontitis. [PMID 28570825]
Franchin M, et al. Cinnamoyloxy-mammeisin Isolated from Geopropolis Attenuates Inflammatory Process by Inhibiting Cytokine Production: Involvement of MAPK, AP-1 and NF-kB. [PMID 27367493]
- U.S. Provisional: U.S. Provisional Patent Application Number 62/678,774, Filed 31 May 2018